Generic Medicine Info
Indications and Dosage
Adult: As olmesartan medoxomil: Initially, 10-20 mg once daily, may be increased to 40 mg once daily if necessary.
Child: ≥6 years Same as adult dose. Max: <35 kg: 20 mg daily; ≥35 kg: 40 mg daily.
Renal Impairment
CrCl (mL/min) Dosage
<20 Not recommended.
20-60 Max: 20 mg once daily.

Hepatic Impairment
Moderate: Initially, 10 mg once daily. Max: 20 mg once daily. Severe: Not recommended.
Biliary obstruction. Pregnancy. Concomitant use with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m2).
Special Precautions
Patient with volume or salt depletion, unstented unilateral or bilateral renal artery stenosis, diabetes mellitus, significant aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy, ascites due to cirrhosis or refractory ascites, primary aldosteronism, history of angioedema. Patient undergoing surgery. Black patients. Renal and hepatic impairment. Children and elderly. Lactation.
Adverse Reactions
Significant: Symptomatic hypotension (particularly in patients with salt or volume depletion), hyperkalaemia, sprue-like enteropathy (characterised as severe, chronic diarrhoea with significant weight loss); renal function deterioration and/or increased serum creatinine. Rarely, angioedema.
Cardiac disorders: Chest pain.
Gastrointestinal disorders: Gastroenteritis, diarrhoea, nausea, dyspepsia, abdominal pain.
General disorders and administration site conditions: Pain, peripheral oedema, facial oedema, influenza-like symptoms, fatigue.
Investigations: Increased hepatic enzymes, BUN, creatine phosphokinase.
Metabolism and nutrition disorders: Hypertriglyceridaemia, hyperuricaemia.
Musculoskeletal and connective tissue disorders: Arthritis, skeletal pain, back pain.
Nervous system disorders: Headache, dizziness.
Renal and urinary disorders: UTI, haematuria.
Respiratory, thoracic and mediastinal disorders: Bronchitis, cough, rhinitis, pharyngitis.
Patient Counseling Information
This drug may cause dizziness or fatigue, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor blood pressure, electrolytes (e.g. serum K levels), renal function, and urinalysis. Assess for signs of angioedema.
Symptoms: Hypotension, tachycardia, bradycardia. Management: Symptomatic and supportive treatment.
Drug Interactions
Enhanced hypotensive effect with other antihypertensive agents. May increase serum K level with K-sparing diuretics, K supplements, K-containing salt substitutes, or other drugs that may elevate serum K levels (e.g. heparin, trimethoprim). May increase the serum concentrations and toxicity of lithium. Decreased glomerular filtration and renal function with NSAIDs (including selective COX-2 inhibitors). Reduced systemic exposure and peak plasma concentration with colesevelam; administer olmesartan at least 4 hours prior to colesevelam.
Potentially Fatal: Increased risk of hypotension, hyperkalaemia, and reduced renal function (including acute renal failure) with aliskiren and ACE inhibitors.
Mechanism of Action: Olmesartan is a competitive and selective angiotensin II receptor antagonist. It blocks all the actions of angiotensin II mediated by the (AT1 receptors, resulting in increased in plasma renin levels and angiotensin I and II concentrations, and some decreased in plasma aldosterone concentrations.
Absorption: Bioavailability: Approx 26%. Time to peak plasma concentration: 1-2 hours.
Distribution: Volume of distribution: Approx 17 L. Plasma protein binding: Approx 99%.
Metabolism: Olmesartan medoxomil undergoes ester hydrolysis in the gastrointestinal tract to active form olmesartan.
Excretion: Via faeces (50-65%) and urine (35-50%) as unchanged drug. Terminal elimination half-life: Approx 10-15 hours.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 158781, Olmesartan. https://pubchem.ncbi.nlm.nih.gov/compound/Olmesartan. Accessed Oct. 24, 2023.

Store between 20-25°C.
MIMS Class
Angiotensin II Antagonists
ATC Classification
C09CA08 - olmesartan medoxomil ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.
Anon. Olmesartan. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 20/10/2022.

Anon. Olmesartan. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 20/10/2022.

Benicar Tablet, Film Coated (Cosette Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 20/10/2022.

Buckingham R (ed). Olmesartan Medoxomil. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 20/10/2022.

Joint Formulary Committee. Olmesartan Medoxomil. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 20/10/2022.

Olmetec (Pfizer [Malaysia] Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 20/10/2022.

Olmetec 10 mg Film-coated Tablet (Daiichi Sankyo UK Limited). MHRA. https://products.mhra.gov.uk. Accessed 20/10/2022.

Disclaimer: This information is independently developed by MIMS based on Olmesartan from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in